Abeona Therapeutics Inc. (ABEO) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call indicates strong financial performance with a significant increase in net income driven by strategic asset sales. The Q&A section reveals positive developments, including successful patient advocacy, strong demand for ZEVASKYN, and effective partnerships. Despite some uncertainties in management responses, the overall sentiment is positive, with optimistic guidance and plans for expansion. The company's ability to meet production goals and achieve profitability in the near future further supports a positive stock price movement.
Key Financial Performance
Cash, cash equivalents, short-term investments, and restricted cash $225.9 million as of June 30, 2025, compared to $98.1 million as of December 31, 2024. The increase was due to the net proceeds of the sale of the Priority Review Voucher received with ZEVASKYN approval.
Research and Development (R&D) expenses $5.9 million for the quarter ended June 30, 2025, compared to $9.2 million for the quarter ended June 30, 2024. The reduction was primarily due to costs capitalized into inventory and select costs reclassified as SG&A expense following ZEVASKYN approval.
Selling, General, and Administrative (SG&A) expenses $17.1 million for the quarter ended June 30, 2025, compared to $8.6 million for the quarter ended June 30, 2024. The increase reflects increased headcount and professional costs associated with the commercial launch of ZEVASKYN.
Net Income $108.8 million for the second quarter of 2025, or $2.07 per basic and $1.71 per diluted common share, compared to $7.4 million net income in the second quarter of 2024, or $0.19 per basic and a net loss of $0.26 per diluted common share. The increase was driven by the gain from the sale of the Priority Review Voucher.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
FDA approval of ZEVASKYN: ZEVASKYN, the first autologous cell-based gene therapy for RDEB, was approved in April 2025. It addresses a significant unmet need for healing RDEB wounds.
Launch progress: Early-stage launch is progressing well with positive feedback from the RDEB community. Two qualified treatment centers (QTCs) have been activated, and the first commercial patient treatment is expected in Q3 2025.
Patient identification and treatment: Approximately 50 patients have been identified for treatment, with plans to treat 10-14 patients in 2025. Manufacturing capacity is set to increase to treat 10 patients per month by mid-2026.
Geographic expansion: Plans to activate additional QTCs to expand ZEVASKYN's geographic footprint and ease patient travel burdens.
Payer coverage: Significant progress in securing insurance coverage, including UnitedHealthcare's decision to cover ZEVASKYN without restrictions. Medicaid coverage has also been secured across all 51 states and Puerto Rico.
Manufacturing capacity: Manufacturing capacity is being scaled to treat 10 patients per month by mid-2026.
Administrative process: The patient journey from identification to treatment currently takes 3-4 months, with efforts underway to streamline this process.
Pipeline partnerships: Beacon Therapeutics exercised an option for a nonexclusive license to AAV204 capsid for retinal diseases. Updates were also provided on partner programs UX111 and TSHA-102 for other genetic conditions.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Logistical Challenges in ZEVASKYN Treatment: The administrative process for ZEVASKYN treatment during the early launch phase requires a long lead time of approximately 3 to 4 months. This includes steps like payer medical authorization, securing financial agreements, and scheduling biopsies, which could delay patient treatment and revenue recognition.
Manufacturing Capacity Constraints: Current manufacturing capacity limits the ability to treat patients, with plans to scale up to treat 10 patients per month only by mid-2026. This could restrict the company's ability to meet growing demand in the near term.
Geographic Accessibility for Patients: With only two qualified treatment centers (QTCs) currently operational, patients may face travel burdens, potentially limiting access to treatment and slowing patient onboarding.
Regulatory and Payer Risks: Although initial payer coverage has been positive, the reliance on medical exception processes and the need for Medicaid program alignment across all states could pose challenges in ensuring consistent and broad access to ZEVASKYN.
Dependence on Partner Programs: The company’s pipeline includes partner programs like UX111 and TSHA-102, which face regulatory hurdles such as FDA-issued CRLs and pending pivotal trials. Delays or failures in these programs could impact future growth and revenue diversification.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Generation: The company anticipates the first ZEVASKYN patient treatment and subsequent revenue generation in Q3 2025, with projected company-wide profitability by early 2026.
Patient Treatment Goals: Abeona aims to treat 10 to 14 patients with ZEVASKYN in 2025 and increase manufacturing capacity to treat 10 patients per month by mid-2026.
Expansion of Treatment Centers: Plans to activate additional Qualified Treatment Centers (QTCs) to expand ZEVASKYN's geographic footprint and ease patient access.
Market Access and Reimbursement: Significant progress in securing insurance coverage for ZEVASKYN, including positive coverage from UnitedHealthcare and Medicaid programs. Optimistic about continued positive momentum with payers.
Pipeline Developments: Progress in partner pipeline programs, including AAV gene therapies for retinal diseases, Sanfilippo syndrome type A, and Rett Syndrome, with pivotal trials and regulatory steps underway.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How are identified patients for ZEVASKYN defined?
A:Identified patients are those with severe RDEB, characterized by large wounds that have never healed. Physicians prioritize these clinically burdened patients who are likely to benefit from ZEVASKYN.
Q:What is the plan for treating the 36+ patients not within the two QTCs?
A:Referrals for these patients have already started, and they are undergoing initial consultations at QTCs. Additional treatment centers are being activated to reduce travel burdens and accommodate more patients.
Q:How critical has patient advocacy and communication been in promoting ZEVASKYN?
A:Patient advocacy has been instrumental. Clinical trial patients who experienced durable wound healing have shared their experiences with potential patients, motivating them to consider ZEVASKYN.
Q:How many cases does a center of excellence need to treat before adopting ZEVASKYN as routine therapy?
A:Centers do not require practice treatments. Some centers, like Chicago Lurie's, will treat their first patient as a commercial case. Physicians typically gain confidence after treating one or two patients, enabling them to scale up.
Q:What are the expected patient numbers for the three additional centers being opened?
A:Each new center is expected to have a couple of dozen patients based on initial discussions and claims analysis. These centers will identify more patients during regular EB clinic meetings.
Q:How does the company plan to activate additional QTCs, and will they meet patient guidance?
A:The company is on track to activate additional QTCs. With the two currently active QTCs, they have sufficient patients to meet the lower end of their guidance range for 2025.
Q:What are the mechanics of payment and reimbursement for ZEVASKYN?
A:Revenue is recognized after a patient is treated. Hospitals can procure the product directly from Abeona or through a specialty pharmacy. Prior authorization agreements are established before product orders, minimizing hospital risk.
Q:Are there any prior authorization requirements related to other RDEB treatments?
A:No pushback has been received from payers regarding prior treatments. Payers recognize ZEVASKYN's value in treating large areas of the body with durable wound healing.
Q:How many prior authorizations have been submitted, and what is the timeline for treatment?
A:The company has seen a 100% success rate for prior authorizations submitted so far. The timeline for prior authorizations is shortening, and the company remains confident in achieving its treatment goals for 2025.
Q:Are there any risks to achieving the production capacity of 10 patients per month by mid-2026?
A:The company is on track to meet this goal. While FDA discussions are required for certain approvals, no inspections are anticipated. The current CGMP facility has the capacity to scale up production.
Q:What are the expectations for the ZEVASKYN launch over the next two years?
A:The company aims to treat 10-14 patients in 2025 and build momentum for 2026. Early trends indicate strong patient demand, and the company is focused on removing hurdles to treatment.
Q:What are the plans for EU and Japan market expansion?
A:The company is exploring options to supply these markets from its Cleveland facility or establish a new manufacturing footprint. Updates will be provided later, as the focus is currently on the U.S. launch.
Q:How should SG&A spend be expected to trend in the coming quarters?
A:SG&A spend may fluctuate due to the mix of engineering runs and production output. The company has stated that three patients per month is the breakeven point for operating costs.
Q:Review of Unclear Management Responses
A:Management avoided providing specific numbers for prior authorizations in process and biopsy timelines, citing the dynamic nature of these metrics. They also refrained from giving quantifiable KPIs for the launch, stating that trends will become clearer by the end of 2025.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Abeona
Children Hospital
Corporate Communications
Global
Investor Relations
Lurie
Officer Dr
QTCs experience
RD expense
Relations Corporate
Research Division
SGA
Senior VP
Stanford
ZEVASKYN approval
ZEVASKYN patient
ZEVASKYN treatment
ability patient
approval ZEVASKYN
biopsy
coverage
feedback
healing application
income
momentum payer
patient ZEVASKYN
patient community
process scheduling
progress
referral
scheduling patient
treatment year
trend
week step
wound healing
ABEO Transcript
Abeona Therapeutics Inc. (ABEO) Q1 2026 Earnings Call Transcript
Unknown5-13
Due to the absence of explicit financial details or strategic updates in the earnings call summary and Q&A session, there's insufficient evidence to predict significant stock movement. The lack of clarity or new information suggests a neutral market reaction, as there's no catalyst for significant positive or negative sentiment.
Abeona Therapeutics Inc. (ABEO) Q4 2025 Earnings Call Transcript
Positive3-17
The earnings call presents a positive outlook with significant improvements in net income, cash reserves, and strategic expansions in treatment centers. The Q&A section reveals some uncertainties, particularly around QTC ramp-up and profitability timelines, but overall market access and reimbursement are strong. The recent FDA approval and commercial transition bolster sentiment, while the gain from the priority review voucher sale is a financial positive. The positive indicators outweigh the uncertainties, suggesting a likely stock price increase.
Abeona Therapeutics Inc. (ABEO) Q3 2025 Earnings Call Transcript
Positive11-12
The earnings call presents a positive outlook with reduced net loss, progress in market access, and strategic expansion plans. The Q&A section confirms no significant impact on profitability timelines despite delays, maintaining a positive sentiment. The company's progress in securing insurance coverage and expanding treatment centers suggests strong future growth potential. Despite some uncertainties in patient timelines and QTC partnerships, overall sentiment remains positive, supported by optimistic guidance and a clear path to profitability by 2026. The absence of a market cap suggests a neutral to positive reaction, likely around 2% to 8%.
Abeona Therapeutics Inc. (ABEO) Q2 2025 Earnings Call Transcript
Positive8-19
The earnings call indicates strong financial performance with a significant increase in net income driven by strategic asset sales. The Q&A section reveals positive developments, including successful patient advocacy, strong demand for ZEVASKYN, and effective partnerships. Despite some uncertainties in management responses, the overall sentiment is positive, with optimistic guidance and plans for expansion. The company's ability to meet production goals and achieve profitability in the near future further supports a positive stock price movement.
ABEO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
